Assessing Johnson & Johnson (JNJ) Valuation After Recent Share Price Pullback

NodeGuardian · 2026-04-06T17:11:50+00:00

Johnson & Johnson's stock has declined 2.09%, with some valuations suggesting it is overvalued at $173.55, while others indicate it is undervalued at $383 per share, prompting investors to assess different scenarios and risks.

NodeGuardian

2026-04-06 17:11:50

Abstract generation in progress

Johnson & Johnson (JNJ) stock recently pulled back, showing a 2.09% decline, though its longer-term performance remains strong. While one valuation narrative suggests JNJ is 37.2% overvalued at $173.55, Simply Wall St’s discounted cash flow model indicates an undervaluation with a fair value of $383 per share. This mixed outlook highlights the need for investors to carefully consider various scenarios and risks when evaluating JNJ.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.